All episodes

Ep. 98: Recommendations on Organizing Headache Care: how to increase access and offer value-based healthcare in headache

Ep. 98: Recommendations on Organizing Headache Care: how to increase access and offer value-based healthcare in headache

19m 48s

Moderator: Alicia Gonzalez (Madrid, Spain)

Guest: Christian Lampl (Linz, Austria)
This last May episode features Alicia González Martínez and her guest Prof. Christian Lampl as they discuss organising headache care, focusing on increasing access and offering value-based healthcare. They delve into strategies to improve the delivery, efficiency, and cost-effectiveness of headache management, aiming to enhance patient well-being and integration of headache care into existing healthcare systems.

Ep. 97: Preclinical, translational and clinical research: insights from animal models and humans

Ep. 97: Preclinical, translational and clinical research: insights from animal models and humans

16m 48s

Moderator: Daniele Martinelli (Pavia, Italy)
Guest: Raquel Gil-Gouveia (Oeiras, Portugal)
Guest: Antoinette Maassen van den Brink (Rotterdam, The Netherlands)
Join us in this episode as Daniele Martinelli engages in a dialogue with esteemed experts, Prof. Antoinette Maassen van den Brink and Dr. Raquel Gil-Gouveia.
They delve into animal models—our window into the brain’s hidden mechanisms. These models reveal neurotransmitter dynamics and potential triggers, paving the way for novel therapies. Additionally, they explore gender-specific nuances, shaping the understanding and personalized management strategies. By bridging theory to practice, they emphasize collaboration—a path toward better patient outcomes, alleviating the burden of this debilitating...

Ep. 96:  Migraine Guideline review: what is published? And what are we working on?

Ep. 96: Migraine Guideline review: what is published? And what are we working on?

16m 48s

Moderator: Anna Gryglas-Dworak (Wroclaw, Poland)
Guest: Dimos-Dimitrios Mitsikostas (Athens, Greece)
This podcast episode presents the current guidelines of the European Headache Federation (published in 2021, updated in 2022) and the American Headache Society (2024) on migraine treatment. Acute and preventive as well as new and old options are discussed.

Ep. 95: Migraine treatment: where are we and where are we going?

Ep. 95: Migraine treatment: where are we and where are we going?

20m 40s

Moderator: Bianca Raffaelli (Berlin, Germany)
Guest: Messoud Ashina (Copenhagen, Denmark)
Guest: Cristina Tassorelli (Pavia, Italy)
In this episode, Bianca Raffaelli hosts experts Messoud Ashina and Cristina Tassorelli on how to navigate the newly enriched therapeutic armamentarium of migraine with disease-specific drugs for the prevention and the acute treatment of attacks. They delve into the questions how, when, where, who and for whom.

Ep. 94: Myoclonus: From Phenomenology to Neurophysiology

Ep. 94: Myoclonus: From Phenomenology to Neurophysiology

26m 43s

Moderator: Giovanni Palermo (Pisa, Italy)
Guest: Sterre van der Veen (Groningen, The Netherlands)
In this episode, Giovanni Palermo and Sterre van der Veen explore the myoclonus phenomenon from its semiology to treatment, while dissecting the complexity of classification systems aimed at recognising its nature and determining its underlying causes.

Ep. 92: General approach to emergencies in dystonia

Ep. 92: General approach to emergencies in dystonia

18m 1s

Moderator: Yildiz Degirmenci (Istanbul, Turkey)

Guest: Vladimira Vuletic (Rijeka, Croatia)

In this episode Yildiz Degirmenci and Vladimira Vuletic cover the approach to dystonia emergencies. Dystonia, marked by muscle contractions and abnormal movements, can be triggered by medications like antipsychotics. Management includes stopping triggering drugs and using medications like diphenhydramine. Status dystonicus, a severe form, requires intensive care with oxygen or ventilation. Primary and secondary dystonias are prone to this condition, possibly needing medication adjustments or deep brain stimulation. They stress the significance of patient history for precise diagnosis and treatment.

Ep. 91: What are tics and how to treat them

Ep. 91: What are tics and how to treat them

22m 33s

Moderator: Yildiz Degirmenci (Istanbul, Turkey)

Guest: Christos Ganos (Berlin, Germany)

Yildiz Degirmenci hosts a discussion with Christos Ganos, a movement disorder specialist, about ticks and Tourette syndrome. They delve into the definition of ticks, discuss diagnostic criteria, and differentiate between primary and functional tic disorders. The conversation also covers treatment options, including psychoeducation, psychological interventions like cognitive behavioral therapy, pharmacological treatments such as antipsychotics, and invasive neuromodulation methods.

Ep. 90: The Burden of Sleep/Wake Disorders Project: Insights from the Pilot Trial in Switzerland

Ep. 90: The Burden of Sleep/Wake Disorders Project: Insights from the Pilot Trial in Switzerland

13m 16s

Moderator: Rolf Fronczek (Leiden, The Netherlands)

Guest: Marina Tüzün (Bern, Switzerland)

Rolf Fronczek and Marina Tüzün discuss the Burden of Sleep Disorders Project, targeting daytime sleepiness and insomnia across Europe. They emphasize primary care collaboration for effective management, including patient perspectives and long-term follow-ups. Dr. Tüzün's personal interest in sleep research drives her involvement, inviting listeners to stay updated on the project's progress.

Ep. 89: Management of behavioral and psychiatric symptoms in dementia

Ep. 89: Management of behavioral and psychiatric symptoms in dementia

26m 14s

Moderator: Francesco Di Lorenco (Rome, Italy)

Guest: Dag Aarsland (London, United Kingdom)

Francesco Di Lorenco and Prof. Dag Aarsland discuss managing behavioral symptoms in dementia, highlighting the burden on patients and families. They stress the importance of timely treatment and challenges in diagnosis. They mention brexpiprazole's FDA approval for Alzheimer's agitation and the need for careful monitoring. Early detection of psychiatric symptoms in neurological diseases is crucial, but distinguishing between disorders is challenging. Therapeutic options like clozapine and cholinesterase inhibitors are mentioned, calling for more research and collaboration.